Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19222529rdf:typepubmed:Citationlld:pubmed
pubmed-article:19222529lifeskim:mentionsumls-concept:C0001418lld:lifeskim
pubmed-article:19222529lifeskim:mentionsumls-concept:C0014871lld:lifeskim
pubmed-article:19222529lifeskim:mentionsumls-concept:C0596545lld:lifeskim
pubmed-article:19222529lifeskim:mentionsumls-concept:C0008902lld:lifeskim
pubmed-article:19222529lifeskim:mentionsumls-concept:C2607850lld:lifeskim
pubmed-article:19222529lifeskim:mentionsumls-concept:C1521798lld:lifeskim
pubmed-article:19222529lifeskim:mentionsumls-concept:C0205171lld:lifeskim
pubmed-article:19222529lifeskim:mentionsumls-concept:C0022771lld:lifeskim
pubmed-article:19222529lifeskim:mentionsumls-concept:C1705938lld:lifeskim
pubmed-article:19222529lifeskim:mentionsumls-concept:C1527178lld:lifeskim
pubmed-article:19222529pubmed:issue8lld:pubmed
pubmed-article:19222529pubmed:dateCreated2009-12-21lld:pubmed
pubmed-article:19222529pubmed:abstractTextThe incidence of adenocarcinoma of the esophagogastric junction (AEG) has been increasing in Western countries. It is unclear, however, whether similar changes are occurring in Asia. We therefore investigated the incidence of AEG in Korea, and assessed the clinical characteristics of three types of AEG based on Siewert's classification. We retrospectively reviewed the medical records of 16 811 patients diagnosed with esophageal squamous cell carcinoma (ESC, n= 1450) or gastric noncardiac adenocarcinoma (GNCA, n= 14 751) between 1992 and 2006. The patients were divided into three 5-year cohorts (cohort A [1992-1996], n= 2734, cohort B [1997-2001], n= 5727, and cohort C [2002-2006], n= 8350), and the ratios of AEG (n= 610) to non-AEG (ESC and GNCA) in each cohort were compared. Using Siewert's classification, the tumors were categorized into one of three types, and patient demographic features and 5-year survival rates were compared. The ratio of AEG to non-AEG cases did not change over time (0.037, 0.034, and 0.039 for cohorts A, B, and C, respectively; P= 0.40). Of the 610 patients with AEG, 23 (3.7%) had type 1 tumors, 47 (7.7%) had type 2, and 540 (88.5%) had type 3. The 5-year survival rate of patients with type 1 AEG was much lower (4.8 +/- 4.7%) than that of those with type 2 (47.9 +/- 7.8%) and type 3 (47.4 +/- 2.5%) tumors. Unlike in Western countries, the ratio of AEG to non-AEG cases has not increased over time in Korea. Type 1 AEG was rarer and associated with a more unfavorable prognosis in Korea than in Western countries.lld:pubmed
pubmed-article:19222529pubmed:languageenglld:pubmed
pubmed-article:19222529pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19222529pubmed:citationSubsetIMlld:pubmed
pubmed-article:19222529pubmed:statusMEDLINElld:pubmed
pubmed-article:19222529pubmed:issn1442-2050lld:pubmed
pubmed-article:19222529pubmed:authorpubmed-author:ChoiK DKDlld:pubmed
pubmed-article:19222529pubmed:authorpubmed-author:KimB SBSlld:pubmed
pubmed-article:19222529pubmed:authorpubmed-author:EngR KRKlld:pubmed
pubmed-article:19222529pubmed:authorpubmed-author:SongH JHJlld:pubmed
pubmed-article:19222529pubmed:authorpubmed-author:JungK WKWlld:pubmed
pubmed-article:19222529pubmed:authorpubmed-author:YoonJ KJKlld:pubmed
pubmed-article:19222529pubmed:authorpubmed-author:CoanR ERElld:pubmed
pubmed-article:19222529pubmed:authorpubmed-author:ChungJ-WJWlld:pubmed
pubmed-article:19222529pubmed:authorpubmed-author:KimJ-HJHlld:pubmed
pubmed-article:19222529pubmed:authorpubmed-author:ShiloShaniSlld:pubmed
pubmed-article:19222529pubmed:authorpubmed-author:JungH-YHYlld:pubmed
pubmed-article:19222529pubmed:authorpubmed-author:JangS-JSJlld:pubmed
pubmed-article:19222529pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19222529pubmed:volume22lld:pubmed
pubmed-article:19222529pubmed:ownerNLMlld:pubmed
pubmed-article:19222529pubmed:authorsCompleteYlld:pubmed
pubmed-article:19222529pubmed:pagination676-81lld:pubmed
pubmed-article:19222529pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:19222529pubmed:meshHeadingpubmed-meshheading:19222529...lld:pubmed
pubmed-article:19222529pubmed:meshHeadingpubmed-meshheading:19222529...lld:pubmed
pubmed-article:19222529pubmed:meshHeadingpubmed-meshheading:19222529...lld:pubmed
pubmed-article:19222529pubmed:meshHeadingpubmed-meshheading:19222529...lld:pubmed
pubmed-article:19222529pubmed:meshHeadingpubmed-meshheading:19222529...lld:pubmed
pubmed-article:19222529pubmed:meshHeadingpubmed-meshheading:19222529...lld:pubmed
pubmed-article:19222529pubmed:meshHeadingpubmed-meshheading:19222529...lld:pubmed
pubmed-article:19222529pubmed:meshHeadingpubmed-meshheading:19222529...lld:pubmed
pubmed-article:19222529pubmed:meshHeadingpubmed-meshheading:19222529...lld:pubmed
pubmed-article:19222529pubmed:meshHeadingpubmed-meshheading:19222529...lld:pubmed
pubmed-article:19222529pubmed:meshHeadingpubmed-meshheading:19222529...lld:pubmed
pubmed-article:19222529pubmed:meshHeadingpubmed-meshheading:19222529...lld:pubmed
pubmed-article:19222529pubmed:meshHeadingpubmed-meshheading:19222529...lld:pubmed
pubmed-article:19222529pubmed:meshHeadingpubmed-meshheading:19222529...lld:pubmed
pubmed-article:19222529pubmed:meshHeadingpubmed-meshheading:19222529...lld:pubmed
pubmed-article:19222529pubmed:meshHeadingpubmed-meshheading:19222529...lld:pubmed
pubmed-article:19222529pubmed:meshHeadingpubmed-meshheading:19222529...lld:pubmed
pubmed-article:19222529pubmed:year2009lld:pubmed
pubmed-article:19222529pubmed:articleTitleUnchanging trend of esophagogastric junction adenocarcinoma in Korea: experience at a single institution based on Siewert's classification.lld:pubmed
pubmed-article:19222529pubmed:affiliationDepartment of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.lld:pubmed
pubmed-article:19222529pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19222529lld:pubmed